Bio-Techne $73/Share Sale to Merck Faces Shareholder Lawsuit
TECH•Halper Sadeh LLC is investigating Bio-Techne’s sale to Merck KGaA for $73.00 per share over potential breaches of fiduciary duty and deal terms that could limit superior competing offers. The firm may seek increased consideration, additional disclosures or other relief on behalf of Bio-Techne shareholders.
1. Transaction Overview
Bio-Techne has agreed to be acquired by Merck KGaA for $73.00 in cash per share, valuing the deal at approximately $5.7 billion. The transaction was structured to provide immediate cash consideration to Bio-Techne shareholders upon closing.
2. Investigation Scope
Halper Sadeh LLC has launched an inquiry into the deal, citing potential violations of fiduciary duty by Bio-Techne’s board and clauses that could deter higher offers. The firm is evaluating whether shareholders received fair consideration or if additional disclosures are warranted.
3. Potential Deal Impacts
If litigation proceeds, shareholders may seek enhanced deal terms or supplemental disclosures, which could delay regulatory approvals or the closing timeline. An adverse ruling or negotiated settlement might compel Merck to raise its offer or adjust transaction provisions.
